DALLAS, Aug. 2, 2013 /PRNewswire-iReach/ -- This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species. The report also gives you a wealth of valuable market data to ensure you develop and market products in this stem cell sector effectively. Understand historical and future growth projections, view competitive analysis of providers of hESC research tools and a breakdown of product categories. Learn this and much more in this leading 133-page market intelligence report "Opportunities in Human Embryonic Stem Cell Products" @ http://www.reportsnreports.com/reports/10600-opportunities-in-human-embryonic-stem-cell-hesc-products.html. This report will help you understand the market entry challenges you face and give you the expert advice to overcome the patent IP structure of the industry. Couple this with market leading intelligence data and this report is a must have if you're looking to outcompete your rivals in this expanding and highly profitable market.
The major reason for offering this report with up-to-date data and information is to guide biotechnology and pharmaceutical companies with cost-effective development of hESC products. "The report will assist companies with smart product development decisions and the development of high-demand products. Other publishers are broad-spectrum publishers and do not hire specialists who are college educated and laboratory trained to have detailed stem cell industry knowledge. We leverage relationships with active laboratory scientists to provide companies with an understanding of how to best approach the patent landscape and produce products that will experience high demand and low competition within the marketplace" says the Head of Product Development for BioInformant Worldwide LLC, the author of this report.
The report is available for purchase @ http://www.reportsnreports.com/Purchase.aspx?name=10600.
Key Findings Include:
- Trends for hESC Grants, Scientific Publications, and Patents
- Market Size Determination for the hESC Product Market
- 5-Year Market Size Projections (2013-2017)
- Embryonic Stem Cell Patent Restrictions and Strategies to Circumvent Claims
- Geographical Breakdown (Leading Countries Conducting hESC Research)
- Breakdown of Embryonic Stem Cell Research, by Application and Species
- Competitive Analysis of hESC Research Supply Vendors
- Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
- Overview of Toxicology Testing Legislation (impacting use of hESC in toxicology applications)
- Crucial Trends and Unmet Market Needs
- And Much More
hESC product market competitors discussed in this report include: Cellartis AB, Vitrolife, Tataa Biocenter, Invitrogen, Stem Cell Technologies, BD Biosciences, Chemicon, R&D Systems, SA Biosciences, Thermo Scientific and Australian Stem Cell Centre.
Specialty pharmaceutical companies developing hESC therapies profiled in this report include: Geron, Novocell, Cell Cure Neurosciences Ltd, Cell Dynamics International and Advanced Cell Technology.
Comprehensive Table of Contents and more on this report @ http://www.reportsnreports.com/reports/10600-opportunities-in-human-embryonic-stem-cell-hesc-products.html.
Explore more reports on the Stem Cell Market @ http://www.reportsnreports.com/tags/stem-cell-market-research.html.
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Call +1 888 391 5441 with your research requirements.
Media Contact: Priyank Tiwari, ReportsnReports.com, +1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com